Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana M Gonzalez-Angulo

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Cancer|August 27, 2004
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinomaErika Resetkova, Ana M Gonzalez-Angulo, Nour Sneige, et al.
Journal of Cancer|August 29, 2013
Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer OutcomesYoung Kwang Chae, Erika N Brown, Xiudong Lei, et al.
Cancer|April 27, 2005
Women age < or = 35 years with primary breast carcinoma: disease features at presentationAna M Gonzalez-Angulo, Kristine Broglio, Shu-Wan Kau, et al.
Cancer|February 27, 2008
Prognostic significance of HER-2 status in women with inflammatory breast cancerShaheenah Dawood, Kristine Broglio, Yun Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2006
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experienceValentina Guarneri, Daniel J Lenihan, Vicente Valero, et al.
Cancer|April 8, 2011
Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancerJeffrey M Albert, Ana M Gonzalez-Angulo, Merih Guray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
cMET and phospho-cMET protein levels in breast cancers and survival outcomesKanwal P Raghav, Wenting Wang, Shuying Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancerSao Jiralerspong, Shana L Palla, Sharon H Giordano, et al.
Breast Cancer Research and Treatment|December 5, 2012
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patientsAshley M Holder, Ana M Gonzalez-Angulo, Huiqin Chen, et al.
Cancer|January 19, 2010
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099Ricardo H Alvarez, Daniel J Booser, Massimo Cristofanilli, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Cancer|August 27, 2004
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinomaErika Resetkova, Ana M Gonzalez-Angulo, Nour Sneige, et al.
Journal of Cancer|August 29, 2013
Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer OutcomesYoung Kwang Chae, Erika N Brown, Xiudong Lei, et al.
Cancer|April 27, 2005
Women age < or = 35 years with primary breast carcinoma: disease features at presentationAna M Gonzalez-Angulo, Kristine Broglio, Shu-Wan Kau, et al.
Cancer|February 27, 2008
Prognostic significance of HER-2 status in women with inflammatory breast cancerShaheenah Dawood, Kristine Broglio, Yun Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2006
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experienceValentina Guarneri, Daniel J Lenihan, Vicente Valero, et al.
Cancer|April 8, 2011
Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancerJeffrey M Albert, Ana M Gonzalez-Angulo, Merih Guray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
cMET and phospho-cMET protein levels in breast cancers and survival outcomesKanwal P Raghav, Wenting Wang, Shuying Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancerSao Jiralerspong, Shana L Palla, Sharon H Giordano, et al.
Breast Cancer Research and Treatment|December 5, 2012
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patientsAshley M Holder, Ana M Gonzalez-Angulo, Huiqin Chen, et al.
Cancer|January 19, 2010
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099Ricardo H Alvarez, Daniel J Booser, Massimo Cristofanilli, et al.
Pageof 15